US EditionPublished • loading... • Updated
D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
Summary by Montana Standard
13 Articles
13 Articles
Montana Standard+12 Reposted by 12 other sources
D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
SHANGHAI, March 19, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at the upcoming American Association for Cancer Research…
Coverage Details
Total News Sources13
Leaning Left1Leaning Right1Center5Last UpdatedBias Distribution72% Center
Bias Distribution
- 72% of the sources are Center
72% Center
14%
C 72%
14%
Factuality
To view factuality data please Upgrade to Premium
